This paper reviews the evidence that the antihypertensive effect of urapidil is due to a systemic vasodilatation with no change in cardiac output, no tachycardia and no under-perfusion of vital organs. Urapidil does not impair the cardiovascular control exerted by arterial baroreceptors and cardiopulmonary receptors. This is probably the reason why no orthostatic hypotension and derangement in blood pressure homeostasis follows its administration.
ASJC Scopus subject areas
- Pharmacology (medical)
- Health, Toxicology and Mutagenesis